From the Research
If you've tested positive for typhoid after receiving the Typbar TCV (Typhoid Conjugate Vaccine) injection, this doesn't mean the vaccine caused the infection, as supported by a study published in 2021 1. The Typbar TCV vaccine contains inactivated components of the typhoid bacteria and cannot cause typhoid fever. Your positive test result could be due to several reasons:
- you may have been infected before vaccination but were still in the incubation period,
- the vaccine hasn't had enough time to provide protection (it typically takes 2-3 weeks to develop immunity),
- or you might have a false positive test result. If you're experiencing symptoms like persistent high fever, headache, abdominal pain, or diarrhea, seek medical attention immediately. Treatment typically involves antibiotics such as ciprofloxacin (500mg twice daily for 7-10 days), azithromycin (500mg once daily for 7 days), or ceftriaxone (1-2g daily for 10-14 days), depending on antibiotic sensitivity patterns, as recommended by a study published in 2021 1. While undergoing treatment, maintain good hydration, rest, and follow up with your healthcare provider to ensure the infection resolves completely. Remember that even after vaccination, maintaining good hygiene practices like handwashing and consuming safe food and water remains important for preventing typhoid fever, as emphasized by a study published in 2023 2.
The effectiveness of the Typbar TCV vaccine has been demonstrated in several studies, including one published in 2021 1, which showed that the vaccine is effective in protecting children against S Typhi infection in an outbreak setting. Another study published in 2021 3 found that the vaccine induces long-lasting immunity, with antibody responses persisting up to 7 years after vaccination. Overall, the Typbar TCV vaccine is a safe and effective tool for preventing typhoid fever, and its use should be promoted to combat the spread of this disease, as recommended by a study published in 2023 2.
In terms of vaccine effectiveness, a study published in 2021 1 found that the Typbar TCV vaccine is 95% effective against culture-confirmed S Typhi and 97% effective against extensively drug-resistant S Typhi. These findings are consistent with those of another study published in 2018 4, which found that the Vi polysaccharide vaccine is effective in preventing typhoid fever, with a cumulative efficacy of 55% over 3 years. However, the Typbar TCV vaccine has been shown to be more effective than the Vi polysaccharide vaccine, with a higher geometric mean titer and a longer duration of protection, as demonstrated by a study published in 2015 5.
In conclusion, the Typbar TCV vaccine is a safe and effective tool for preventing typhoid fever, and its use should be promoted to combat the spread of this disease. If you've tested positive for typhoid after receiving the vaccine, it's essential to seek medical attention immediately and follow the recommended treatment protocol. Additionally, maintaining good hygiene practices and consuming safe food and water remains crucial for preventing typhoid fever, even after vaccination.